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Abstract
A heteroplasmic T to C transition at nucleotide position 14709 in the mitochondrial tRNA glutamic acid (tRNAGlu) gene has previously
been associated with maternally inherited diabetes and deafness (MIDD). To investigate the pathogenic mechanism of the T14709C mutation,
we have constructed transmitochondrial cell lines by transferring fibroblasts mitochondria from a patient with the mutation into human cells
lacking mitochondrial DNA (mtDNA) (rhoj cells). Clonal cybrid cell lines were obtained containing various levels of the heteroplasmic
mutation, or exclusively mutated or wild-type mtDNA. Measurement of respiratory chain enzymatic activities failed to detect a difference
between the homoplasmic mutant and homoplasmic wild-type cybrid cell lines. However, a subtle decrease in the steady-state levels of
tRNAGlu transcripts in some mutant clones. Our studies suggest that the T14709C mutation is insufficient to lead impairment of
mitochondrial function in homoplasmic osteosarcoma cybrid clones, and that we cannot exclude that the T14709C mutation affects
mitochondrial function by a yet unidentified mechanism.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Over the last decade, mutations of the mitochondrial
genome have become increasingly recognised as important
causes of human disease. Many of these abnormalities take
the form of mtDNA rearrangements, but an increasing
number of mtDNA point mutations have now been
described, affecting protein coding, rRNA or tRNA genes
(MITOMAP http://www.gen.emory.edu/mitomap.html).
MtDNA abnormalities, including deletions, duplications
and point mutations, are a well-recognised cause of diabetes
[1–5]. The most commonly described mtDNA defect in
patients with maternally inherited deafness and diabetes
(MIDD) resides in the tRNALeu(UUR) gene [2–6], an A to
G transition at position 3243 that was first associated with
the mitochondrial encephalopathy, lactic acidosis and
stroke-like episodes (MELAS) syndrome [7]. Moreover, a
point mutation (T14709C) in the mitochondrial tRNA gene
for glutamic acid (tRNAGlu) has been identified in some
patients with diabetes mellitus [8–11]. In these cases, the
T14709C mutation was heteroplasmic and present at high
levels in the patient’s muscle and white blood cells. Bio-
chemical studies of muscle mitochondria showed reduced
complex I and IV activities [8–10], whilst a correlation was
also shown between the level of mutation and the activity of
cytochrome c oxidase in single muscle fibres [9]. In addi-
tion, profound alteration of oxidation process was demon-
strated in vivo by 31P magnetic spectroscopy [10].
The development of human cell lines lacking mtDNA
(rhoj cell lines) that can be repopulated with exogenous
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mtDNA by mitochondria-mediated transformation [12] has
provided a useful tool to study pathogenic mtDNA muta-
tions, as all cybrids contain the same mtDNA haplotype
within the same nuclear background, differing by only the
single nucleotide point mutation [13–15]. We have used this
methodology to investigate the molecular pathogenic mech-
anism of the T14709C mutation. Using fibroblasts from a
previously characterised patient with this mutation as a
source of donor mitochondria [10], we have isolated several
clonal cell lines that contained exclusively homoplasmic
mutated or wild-type mtDNA and heteroplasmic mtDNA
and performed detailed biochemical studies of these cell
lines to assess the effect of the T14709C mutation on
mitochondrial function.
2. Materials and methods
2.1. Patient
The patient presenting diabetes and severe myopathy was
described in detail previously [10]. Briefly, a muscle biopsy
revealed ragged red fibers and a decreased activity of
respiratory chain complex IV (39% of mean control values).
Molecular analysis demonstrated the presence of a hetero-
plasmic T14709C mutation at a level of 78% mutant load in
skeletal muscle and 65% in blood.
2.2. Cell lines and culture conditions
Fibroblasts from skin explant obtained from this patient
were cultured in high-glucose DMEM supplemented with
10% foetal bovine serum (FBS), 100 Ag/ml pyruvate and 50
Ag/ml uridine in 5% CO2 at 37 jC. The 143B.TK 
osteosarcoma cell line and the daughter 143B.206.TK
rhoj cells were provided by M. King (T. Jefferson Univer-
sity, Philadelphia, PA, USA). 143B.206 rhoj cells, com-
pletely depleted of mtDNA by long-term exposure to
ethidium bromide, were grown in DMEM containing 4.5
g/l glucose and 110 Ag/ml pyruvate, supplemented with
10% FBS (Gibco), 50 Ag/ml uridine and 100 Ag/ml 5-
bromo-2V-deoxy uridine (BrdU, Sigma Immunochemicals,
Saint Louis, MO).
2.3. Cell fusion
Transmitochondrial cell lines were obtained using the
method of King and Attardi [12]. Rhoj cells were collected
by low-speed centrifugation, resuspended in DMEM, and
counted. Fibroblasts (106 cells) were mixed with an equal
number of rhoj cells, and culture medium carefully elimi-
nated by centrifugation. Cells were resuspended for 1 min in
0.2 ml of sterile polyethyleneglycol 1500 (50% w/v) (Roche
Diagnostics, Meylan, France). After cell fusions, screening
of complemented cells was performed by growing cells in
standard DMEM for 24 h and then in selective medium
(pyruvate- and uridine-free DMEM supplemented with 5%
dialysed FBS and 100 Ag/ml BrdU). After 15 days, about 27
independent colonies were observed and selected in the
same medium used for the rhoj cells.
2.4. DNA analysis
Total DNA from blood cells and from cybrids cells was
prepared using standard protocols [10]. Hair follicles and
buccal cells were prepared and subjected to PCR amplifi-
cation as described [16,17]. For the quantitation of the
T14709C tRNAGlu mutation, a 284-bp fragment was ampli-
Fig. 1. Tissue distribution of T14709C mutation. PCR fragments of DNA of
fibroblasts (F), muscle (M), white blood cells (WBC), hair follicles (HF)
and buccal cells (BC) of the patient were digested with NdeI into two
fragments of 284 bp (mutated DNA) and 259 bp (wild-type DNA, control
C) and separated by electrophoresis through a 15% nondenaturing
acrylamide gel.
Fig. 2. Growth kinetics of the cell types used in complementation
experiments. Rhoj in DMEM+dialysed FBS +BrdU ( +—+), rhoj in
DMEM+dialysed FBS+BrdU+ pyruvate + uridine (open squares), fibro-
blasts from patient in DMEM+dialysed FBS+BrdU (filled circles),
fibroblasts from patient in DMEM+dialysed FBS (open circles), cybrid
cells in DMEM+dialysed FBS+BrdU (filled squares). Concentrations
used: dialysed FBS 5% (vol/vol); BrdU, 100 Ag/ml; uridine 50 Ag/ml;
pyruvate, 100 Ag/ml.
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fied using the polymerase chain reaction (PCR) method.
Conditions were as follows: one cycle at 94 jC for 3 min,
followed by 30 cycles at 94 jC for 30 s, 62 jC for 30 s and
72 jC for 30 s; the final extension proceeded for 10
min. Primers for the reaction were 5VCACGGACTACAAC-
CACGACCAATCATA 3V(n t 14682 – 14708) and
5VTTACGTCTCGAGTGATGTGG 3V(nt 14966–14947).
The underlined position in the first primer represents a
modification from the wild-type sequence to create an NdeI
restriction site in wild-type mtDNA. The amplification
products were digested with NdeI, which cleaves the 284-
bp fragment into two fragments of 259 and 25 bp. The
T14709C mutation abolishes this NdeI restriction site. To
determine the proportion of normal and mutated mtDNA,
the amplified fragment was labeled with [a-32P]dCTP in the
last cycle to prevent underestimation of the proportion of
mutant mtDNA due to heteroduplex formation. Following
digestion, the restriction fragments were submitted to elec-
trophoresis through a 15% polyacrylamide gel, the gel was
dried onto a support and exposed to radiographic film. The
relative proportions of mutant and wild-type mtDNA were
quantified by scanning and analysing a shortly exposed X-
ray film with the Image 1.45 software.
Nuclear genotypes were characterised by high polymor-
phic markers analysis. PCR fragments with CA repeats from
chromosome 5 (D5S455) were amplified and sequenced
using an ABI Prism automated DNA sequencer (Perkin
Elmer) [18]. The highly polymorphic repetitive sequence
D11S533 present on chromosome 11q was evidenced in the
different cell lines, as described [19].
2.5. Respiratory chain enzyme analysis of transmitochon-
drial cybrid clones
Mitochondrial fractions were isolated from cultured cells
and the activities of the individual respiratory chain com-
plexes and the matrix marker citrate synthase were deter-
mined spectrophotometrically as previously described
[20,21].
2.6. High-resolution Northern blot analysis
Total cytosolic RNA was isolated from 1 to 2 106 cells
using TRIZOLR Reagent (Life Technologies, UK). Large
RNA species were precipitated by the addition of 10 M
LiCl, allowing smaller RNAs (5S, tRNA) to be precipitated
from the resulting supernatant. Small RNAs (1 Ag) were
separated through a 13%, 8 M urea denaturing polyacryla-
mide gel using 1TBE as running buffer, electroblotted
onto GeneScreen-plus membranes (NEN Dupont) in
0.25TBE and immobilised by UV crosslinking. Regions
of mtDNA encompassing the tRNAGlu and tRNALeu(UUR)
Fig. 3. Genetic characterization of patient’s fibroblasts and cybrid cells. (A) Analysis for the presence and quantity of the mutated DNA with the 14709
mutation in DNA isolated from patient’s fibroblasts (F) and eight derived heteroplasmic cybrid cells compared to control DNA (C) after NdeI digestion of a
PCR-amplified fragment containing the tRNA glutamic acid gene. The size of the fragments is shown on the right, and the proportion of mutated DNA is
indicated below each lane. (B) PCR amplification of the D11S533 locus of patient’s fibroblasts, cybrid clones, their nuclear parent 143B and rhoj cells.
Amplification of the nuclear DNA of the donor fibroblasts (F) produces a two-band pattern (530 and 430 bp) which differs from the single band obtained from
the nuclear DNA of the other cell lines, including 143B cells, rhoj cells, three wild-type (W3, W11, W22) and four mutated transformant cybrid clones (M12,
M15, M20 M21).
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genes amplified by PCR were used as probes for Northern
blots. The tRNAGlu probe (69 bp) was amplified using the
forward primer L14635 (positions 14635 – 14655).
5VTACTAAACCCACACTCAACAG 3Vand the reverse
primer H14810 (positions 14810–14791) 5VGGAGGTC-
GATGAATGAGTGG 3V. The tRNALeu(UUR) probe (75 bp)
was amplified using the forward primer L3200 (positions
3200–3219) 5V TATACCCACACCCACCCAAG 3V and
the reverse primer H3353 (positions 3353 – 3334)
5VGCGATTAGAATGGGTACAAT 3V. Purified PCR prod-
ucts were radiolabelled with [a-32P] dCTP (3000 Ci/mmol)
(Amersham, UK) by the random-primer method and unin-
corporated nucleotides were removed by gel filtration
through a Sephadex G-50 DNA grade column (Pharmacia,
UK). Hybridization was carried out at 42 jC overnight in a
solution of 5 SSPE, 50% formamide, 10% dextran sul-
phate, 5Denhardt’s solution, 1% SDS containing 2 106
cpm radiolabelled probe. After hybridization, two 15-min
washes were performed at room temperature with 2 SSPE,
followed by a 15-min wash at 65 jC with 2 SSPE and 2%
SDS. Blots were subjected to PhosphorImager analysis and
the radioactive signal for the tRNAGlu probe (69 bp)
normalised to that of the tRNALeu(UUR) probe (75 bp) for
each sample using ImageQuant software (Molecular
Dynamics).
3. Results
3.1. Tissue distribution of the T14709C mutation and
respiratory chain activity measurements in fibroblasts
Fig. 1 shows that the proportion of mutant mtDNA was
highest in the muscle of the patient (82%) as compared to
the proportion found in white blood cells (61%). The
T14709C mutation was found in buccal cells (69 %) and
in hair follicles (65%) of the patient. Skin fibroblasts
cultures were established from the patient carrying the
T14709C mutation. Analysis of fibroblasts established from
the patient revealed a mutant load of 71%. Respiratory chain
enzyme activities determined from mitochondria-enriched
preparations [19] showed a reduced complex I activity
(57%) and a slightly decreased complex IV activity (72%)
in the patient compared to controls.
3.2. Cell fusion and characterization of the cybrid cells
To obtain homoplasmic mutant transmitochondrial cell
lines, patients’ fibroblasts were fused with rhoj cells fully
depleted of mtDNA derived from the 143B.TK cell line.
The growth capacity of the different cell lines in various
media was assessed (Fig. 2). The rhoj cells exhibited both
auxotrophy for pyruvate and uridine and resistance to BrdU,
as they were obtained from the thymidine kinase-deficient
(TK ) osteosarcoma 143B cell line. Patient’s fibroblasts
exhibited BrdU sensitivity and were able to grow in DMEM
lacking pyruvate and uridine (Fig. 2). After fusion, selection
of cybrids was performed in the selective medium contain-
ing BrdU but lacking pyruvate and uridine. After 15 days,
we collected 27 transformant cybrid clones. The different
clones were able to grow in the selective medium with
growth kinetics similar to those of rhoj cells in a pyruvate-
and uridine-supplemented medium.
We analysed the mtDNA genotype of the 27 cybrids
clones by PCR-RFLP analysis. Eleven clones were hetero-
plasmic ranging from 4% to 95% mutated DNA (Fig. 3A).
Nine of 27 clones contained 100% mutant mtDNA, whereas
seven were judged homoplasmic for wild-type mtDNA (Fig.
4A).We confirmed the presence of normal amounts of
mtDNA in each clone by Southern blot analysis (the
mtDNA probe was a 15.6-kb purified PCR product ampli-
fied with the Expand Long Template PCR system and the
nuclear probe was a 18S probe) (data not shown).
Each clone was subsequently examined to verify that the
mitochondrial genotype was identical to the donor fibro-
blasts by sequence analysis [22,23] and that the nuclear
genotype was identical to that of the nuclear parent, the
143B cell line. We demonstrated that the DNA of the wild-
type and mutated cybrid clones were homozygous for the
Fig. 4. Molecular analysis of wild-type and mutant 14709 cybrid clones.
(A) PCR-RFLP analysis of three wild-type (lanes 1–3) and three
homoplasmic mutant clones (lanes 4–6). The band at 284 bp represents
mutated mtDNA whilst the band at 259 bp represents wild-type mtDNA.
(B) Determination of steady-state mt-tRNAGlu levels in cybrid clones using
high-resolution Northern blots. Small RNAs (1Ag) were separated through a
denaturing polyacrylamide gel, electroblotted onto membranes and
hybridized with radiolabeled probes specific for mt-tRNAGlu and mt-
tRNALeu(UUR) transcripts as described in Materials and Methods. (C) The
bar chart illustrates the ratio of mt-tRNAGlu signal to mt-tRNALeu(UUR)
signal for each of the six cybrid clones.
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same length polymorphism at the D11S533 locus of their
nuclear parent, 143B, which differed from the heterozygous
pattern found in the donor patient’s fibroblasts (Fig. 3B).
Moreover, the allelic marker pattern D5S455 found in the
rhoj cells was evidenced by sequence analysis of the cybrid
cells DNA (data not shown). This clearly indicated that the
nucleus in cybrid cells originated from rhoj cells.
3.3. Respiratory chain enzyme analysis of transmitochon-
drial cybrid clones
The activities of complexes I, II and IV were measured in
mitochondrial fractions prepared from four wild-type cybrid
clones and five homoplasmic mutant cybrids, and compared
to the activity of the mitochondrial matrix marker enzyme,
citrate synthase (Table 1). No significant differences in the
enzymatic activities between homoplasmic mutant cells and
homoplasmic wild-type cybrid clones were observed.
3.4. tRNAGlu steady-state levels
To investigate the effect of the T14709C mutation on the
processing of tRNAGlu from its precursor, the steady-state
level of tRNAGlu was determined by Northern blot hybrid-
ization in the three homoplasmic wild-type and three homo-
plasmic mutant cybrid clones. The tRNAGlu did not show
any obvious size change in the mutant form compared to
controls, although there appeared to be a decrease in the
quantity of the mature tRNAGlu transcripts in two of the
three mutant clones to about 50% of the amount present in
the wild-type clones (Fig. 4).
4. Discussion
In an attempt to further characterise the pathogenic
mechanism of the T14709C tRNAGlu mutation of mitochon-
drial DNA, we have constructed transmitochondrial cell
lines by transferring fibroblast mitochondria from a patient
previously shown to be heteroplasmic for this mutation [10],
into the 143B.TK osteosarcoma rhoj cell line. Several
clones were isolated that contained either exclusively the
wild-type allele (homoplasmic for 14709T) or the mutant
allele (homoplasmic for 14709C), and assessed for respira-
tory chain enzyme activities. No discernible difference in
respiratory chain function was noted between the homo-
plasmic mutant and wild-type cybrids. High-resolution
Northern analysis revealed steady-state levels of tRNAGlu
transcripts to be subtly decreased in some mutant clones,
thus highlighting the limitations of these transmitochondrial
cybrids for the investigation of pathogenic mutations.
The T14709C transition was first described in two
families in whom the index case presented with an adult-
onset myopathy and diabetes mellitus [8,9]; mental retarda-
tion and cerebellar ataxia was evident in members of one
pedigree [8]. The mutation affects a highly conserved
nucleotide flanking the anticodon of the tRNAGlu, a func-
tionally important region of the tRNA structure (Fig. 5).
Incidentally, a mutation (A4295G) at the analogous position
of the mitochondrial tRNAIle gene has also been docu-
mented as causing disease [24]. The T14709C mutation
was shown to be heteroplasmic and present at high levels in
skeletal muscle. Muscle biopsy of affected individuals
revealed mitochondrial accumulations (ragged-red fibres)
and a proportion of fibres expressing focal defects of
cytochrome c oxidase (COX-negative fibres) [8,9]. Bio-
chemical studies in muscle also revealed a defect in the
activities of complexes I and IV [8–10], consistent with an
impairment of mitochondrial translation. These data,
together with the demonstration that COX-negative fibres
harboured significantly higher levels of mutated mtDNA
than functionally normal, COX-positive have assigned the
mutation as pathogenic in accordance with fulfilled accepted
criteria [25]. To elucidate the molecular mechanism of any
Table 1
Mitochondrial respiratory chain enzyme activities in transmitochondrial
cybrids
Wild type, n= 4
(meanF S.D.)
M5 M7 M8 M20 M21
Complex I/CS 0.145F 0.064 0.089 0.162 0.120 0.078 0.125
Complex II/CS 0.292F 0.103 0.266 0.276 0.193 0.318 0.415
Complex IV/CS 1.34F 0.32 0.821 1.025 2.127 1.230 2.360
Four wild-type and five totally mutated (M5, M7, M8, M20, M21) cybrid
clones were analysed. Enzyme activities from mitochondria-enriched
preparations are expressed as nanomoles NADH oxidised per minute per
unit citrate synthase (CS) activity for complex I, nanomoles DCPIP reduced
per minute per unit of citrate synthase for complex II and the apparent first-
order rate constant per second per unit citrate synthase for complex IV
( 103). DCPIP= 2,6-dichlorophenol-indophenol; S.D. = standard devia-
tion. Assays were performed in triplicate.
Fig. 5. Location of the T14709C mutation in the mitochondrial tRNAGlu
gene, highlighting the mucleotide position that is affected (arrow) within
the cloverleaf secondary structure of the molecule.
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potential pathogenic mutation, however, studying homo-
plasmic transmitochondrial cybrids remains very much the
method of choice [12–15].
The most puzzling aspect of our results is that the studies
of the T14709C mutation in cybrids did not reflect the
biochemical defect (partial complex IV deficiency) ex-
pressed in mature muscle of our patient, or those seen in
previously reported cases [8,10]. We believe this may be
due to a number of reasons, not least the fact that the
expression of mitochondrial DNA variants is dependent
upon a combination of nuclear background and mtDNA
genotype. Non-random segregation of pathological and
wild-type mtDNA molecules in osteosarcoma and lung
carcinoma cells has been observed previously in particular
for the A3243G mtDNA mutation [26] and partially dupli-
cated mtDNAs [27]. Moreover, Hao et al. [28] have
observed that under selective pressure, some transmitochon-
drial cybrids containing essentially homoplasmic levels of
the G5703A mutation could regain normal mitochondrial
function, in a process that appears to be associated with
changes in the nuclear background. As cells respond to the
presence of a mutation that impairs tRNA function by a
variety of compensatory mechanisms, this might explain
why essentially homoplasmic cybrid clones exhibited slight
differences in the level of tRNAGlu transcripts.
It is reasonable that the primary molecular consequences
of the T14709C mutation might be due to a translation
defect by impairing the translation of glutamate codons, or
to reduced levels of aminoacylated tRNAGlu. Recent studies
have investigated this possibility in patients with MELAS
due to the A3243G mutation, following the isolation of
another mutation (at position 12300) in the anticodon of the
mitochondrial tRNALeu(CUN) gene that was able to suppress
both the protein synthesis defect and respiratory impairment
of cells harbouring very high levels of mutant mtDNA in a
lung carcinoma line [29]. Although the suppressor tRNA is
efficiently aminoacylated in the lung carcinoma cell line,
aminoacylation of the tRNALeu(UUR) is severely decreased
[15,30]. These data, together with studies in A3243G
MELAS biopsy samples that reported decreased amounts
of aminocylated tRNALeu(UUR) in some, but not all, biopsy
samples suggest that the molecular consequences of the
mutation can be as diverse in vivo as they are in cultured
cells and are dependent upon the nuclear background [31].
The large variation of the clinical phenotype in MIDD
associated with the T14709C mutation is striking [8,10].
Although some of this diversity may be accounted for by
intra-tissue variability of mutation load, the involvement of
additional nuclear factors is likely to contribute to the
phenotypic variability of the MIDD disease.
In conclusion, the T14709C mutation currently fulfils all
accepted criteria to be documented as pathogenic. It has
been detected in several families, is heteroplasmic and is
associated with a measurable biochemical defect in patient’s
muscle. Our studies indicate that T14709C tRNAGlu muta-
tion is insufficient to lead impairment of mitochondrial
function in these homoplasmic osteosarcoma cybrid clones
and although reduced levels of mutant tRNAs were
observed, this may highlight a limitation of the cybrid cell
system for studying pathogenic mtDNA mutations. More
extensive work, including the analysis of further cybrids
with different nuclear backgrounds, will be required before
the exact correlation between clinical symptoms and state
level of tRNAGlu is understood.
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